Sun Pharma Advanced Research has reported results for third quarter ended December 31, 2012.
The company has registered a loss of Rs 24.09 crore in Q3FY13 as compared to a net loss of Rs 17.90 crore in the corresponding quarter previous year. However, the total income of the company has decreased by 6.43% at Rs 4.22 crore for quarter under review as compared to Rs 4.51 crore for the quarter ended December 31, 2011.
SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems. The company’s core focus is innovation and new product development for global markets.
